Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phil Skolnick

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Neuron|October 21, 2016
Re-energizing the Development of Pain Therapeutics in Light of the Opioid EpidemicPhil Skolnick, Nora D Volkow
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
New medications for substance use disorders: challenges and opportunitiesNora D Volkow, Phil Skolnick
Trends in Pharmacological Sciences|October 20, 2009
Glutamate-based antidepressants: 20 years onPhil Skolnick, Piotr Popik, Ramon Trullas
Drug and Alcohol Dependence Reports|September 12, 2024
Synthetic opioids have disrupted conventional wisdom for treating opioid overdosePhil Skolnick, Jordan Paavola, Christian Heidbreder
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 23, 2019
Be positive about negatives-recommendations for the publication of negative (or null) resultsAnton Bespalov, Thomas Steckler, Phil Skolnick
Biological Psychiatry|March 5, 2013
Glutamate-based antidepressants: preclinical psychopharmacologyAndrzej Pilc, Joanna M Wierońska, Phil Skolnick
Journal of Clinical Pharmacology|March 4, 2024
Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal NaloxoneMark Ellison, Emily Hutton, Lynn Webster, et al.
Psychopharmacology|December 21, 2016
From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disordersJane B Acri, Alan J Cross, Phil Skolnick
European Journal of Pharmacology|October 7, 2004
Anxioselective anxiolytics: can less be more?Anthony S Basile, Arnold S Lippa, Phil Skolnick
Journal of Fluorescence|June 18, 2013
2-[2-[4-[2-[2-[ 1,3-Dihydro- 1,1-bis (4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl] ethylamino]-5'-<i>N</i>-ethylcarboxamidoadenosine (FITC-APEC): A Fluorescent Ligand For A<sub>2a</sub>-Adenosine ReceptorsR Tyler McCabe, Phil Skolnick, Kenneth A Jacobson
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Neuron|October 21, 2016
Re-energizing the Development of Pain Therapeutics in Light of the Opioid EpidemicPhil Skolnick, Nora D Volkow
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
New medications for substance use disorders: challenges and opportunitiesNora D Volkow, Phil Skolnick
Trends in Pharmacological Sciences|October 20, 2009
Glutamate-based antidepressants: 20 years onPhil Skolnick, Piotr Popik, Ramon Trullas
Drug and Alcohol Dependence Reports|September 12, 2024
Synthetic opioids have disrupted conventional wisdom for treating opioid overdosePhil Skolnick, Jordan Paavola, Christian Heidbreder
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 23, 2019
Be positive about negatives-recommendations for the publication of negative (or null) resultsAnton Bespalov, Thomas Steckler, Phil Skolnick
Biological Psychiatry|March 5, 2013
Glutamate-based antidepressants: preclinical psychopharmacologyAndrzej Pilc, Joanna M Wierońska, Phil Skolnick
Journal of Clinical Pharmacology|March 4, 2024
Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal NaloxoneMark Ellison, Emily Hutton, Lynn Webster, et al.
Psychopharmacology|December 21, 2016
From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disordersJane B Acri, Alan J Cross, Phil Skolnick
European Journal of Pharmacology|October 7, 2004
Anxioselective anxiolytics: can less be more?Anthony S Basile, Arnold S Lippa, Phil Skolnick
Journal of Fluorescence|June 18, 2013
2-[2-[4-[2-[2-[ 1,3-Dihydro- 1,1-bis (4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl] ethylamino]-5'-<i>N</i>-ethylcarboxamidoadenosine (FITC-APEC): A Fluorescent Ligand For A<sub>2a</sub>-Adenosine ReceptorsR Tyler McCabe, Phil Skolnick, Kenneth A Jacobson
Pageof 6